Indoco Remedies Ltd (INDOCO) Q4FY26 Management Mirror - Mar-2026 Qtr
Domestic Revenue Growth
In the Mar'26 Qtr, management tempered its domestic formulation outlook, expecting growth to perform in line with the Indian Pharmaceutical Market (IPM) for the upcoming year, scaling back from the Dec'25 Qtr guidance of double-digit growth outperforming the IPM, which had previously been upgraded from higher single-digit expectations in the Sep'25 Qtr. [Status: Downgraded]
4 more themes on the ELITE plan.